Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?

CONCLUSIONS: Locally advanced ESCC patients with time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery > 8 weeks were associated with worse long-term survival.PMID:38536527 | DOI:10.1007/s00432-024-05696-4

Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Jiacong Liu Linhai Zhu Xuhua Huang Zhongjie Lu Yanye Wang Yuhong Yang Jiayue Ye Chen Gu Wang Lv Chong Zhang Jian Hu Source Type: research